Peptides
AOD-9604
AOD-9604 is a modified fragment of human growth hormone studied in fat-metabolism research. Below, we compare vendors currently stocking research-grade AOD-9604 — not just a single sales page.
AOD-9604 is a modified fragment of human growth hormone studied in fat-metabolism research. Below, we compare vendors currently stocking research-grade AOD-9604 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£34.99 | In-house testing | Buy Here → | |
 Amino Club |
From $49.99 | Third-party COA | Buy Here → | |
 American Peptides |
$60.00 | Third-party COA | Buy Here → |
AOD-9604 is a modified fragment of human growth hormone corresponding to amino acids 176-191 of the hGH sequence, engineered to isolate the fat-metabolizing region of the GH molecule without its broader growth-promoting or insulin-desensitizing effects.
Research-grade AOD-9604 is typically supplied as a lyophilized powder in sealed vials, commonly at 2mg to 5mg strengths, intended for laboratory research use only.
AOD-9604 is studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) in adipose tissue, reportedly without significantly activating the IGF-1 pathway associated with full-length growth hormone's anabolic and blood-sugar effects.
AOD-9604 was originally developed by Australian biotech Metabolic Pharmaceuticals specifically to study GH's lipolytic fragment in isolation, and it remains the primary reference compound for that specific line of research.
Because it was designed to separate GH's fat-metabolism effects from its growth-promoting activity, AOD-9604 is studied as a tool for dissecting which regions of the GH molecule drive which physiological outcomes.
AOD-9604 completed Phase IIb human obesity trials in Australia but did not demonstrate sufficient efficacy over placebo to proceed to further development, and it has not received FDA approval. Documented trial data found it to be generally well-tolerated at studied doses, though it is not approved for any indication.
Doses used in the completed Phase IIb clinical trials are documented in the associated trial literature; this does not constitute a current recommendation for use of unregulated research material, for which no approved dosage exists.
Compound X does not sell AOD-9604 directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
AOD-9604 clinical trial outcomes are indexed on PubMed under "AOD9604 obesity trial" and "AOD-9604 lipolytic fragment."
New guides, vendor comparisons and compound breakdowns every week.